Biocon Overhauls Top Management as It Integrates Biocon Biologics

Biocon Limited ( (IN:BIOCON) ) has provided an update.

Biocon’s board has approved a major reshaping of its leadership as part of the ongoing integration of Biocon Biologics to create a unified biopharmaceutical group. Chief Executive Officer and Managing Director Siddharth Mittal will step down on March 31, 2026, to assume another role within the Biocon group, with Biocon Biologics CEO and MD Shreehas Pradeep Tambe taking over as Biocon’s CEO and MD for a five-year term from April 1, 2026, subject to shareholder approval.

The board also accepted the resignation of Interim Chief Financial Officer Mukesh Kamath, who will move to another role within the group, and appointed Biocon Biologics CFO Kedar Narayan Upadhye as Biocon’s CFO from April 1, 2026. Additional changes include designating Biocon Biologics’ company secretary Akhilesh Nand as Head of Governance, Risk and Compliance and a key managerial and senior management figure, while Biocon Biologics’ HR and IT leaders will become Biocon’s Chief Human Resources Officer and Chief Technology Officer respectively, and several existing senior managers will cease to be designated as senior management, underscoring a broad realignment of management around the integrated structure.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company focused on developing and manufacturing biologics, biosimilars and other specialty pharmaceuticals for global markets. Through its subsidiary Biocon Biologics Limited, the group targets therapies for chronic diseases and aims to build a unified global biopharmaceutical platform to enhance its competitive position.

Average Trading Volume: 171,147

Technical Sentiment Signal: Buy

Current Market Cap: 614.9B INR

For a thorough assessment of BIOCON stock, go to TipRanks’ Stock Analysis page.